Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Allows the government to negotiate prices for prescription drugs paid by taxpayers.
The problem
Prescription drug prices are very high. Taxpayers spend billions on medicines through government programs. Drug companies set prices with little government input or control.
The proposal
Gives the government power to negotiate and set lower prices for prescription drugs in federal programs like Medicare and Medicaid.
The impact
Patients, seniors, taxpayers, and drug companies. Patients may pay less. Taxpayers may save money. Drug companies may earn less revenue.
Medicare beneficiaries could pay less for prescriptions. This helps fixed-income seniors afford needed medicines. Reduces out-of-pocket costs.
Government programs spend less on drugs when prices are lower. This reduces federal spending on healthcare. Frees up money for other programs.
Lower drug prices mean lower insurance premiums. Employers and workers benefit from cheaper health coverage. The entire healthcare system becomes less expensive.
When government buys large quantities, it can demand better prices. This is how other countries negotiate drug costs. Creates fair market competition.
Lower prices mean less profit for drug companies. Companies might invest less in research for new medicines. Could delay cures and treatments.
If prices drop too far, companies may stop making certain drugs. Patients could face shortages of important medicines. Supply problems could harm access.
Government price-setting removes market competition. Some argue this is too much government control. Private companies lose ability to set their own prices.
Lower prices could make drugs harder to access. Patients might wait longer for medications. Government bureaucracy could slow the approval process.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.